Analytical Run Acceptance Criteria in Regulated Bioanalysis: QC Levels, Placement, and What ICH M10 Requires
Introduction Under the harmonized ICH M10 guideline, which was adopted at Step 4 on May 24, 2022, issued by the […]
Introduction Under the harmonized ICH M10 guideline, which was adopted at Step 4 on May 24, 2022, issued by the […]
Introduction Effective Calibration Curve Design and Regression Weighting in LC-MS/MS bioanalysis requires matching the mathematical order of the calibration function
Introduction Understanding Peptide CDMO Cost / Pricing in the United States involves examining a complex financial landscape in which preclinical
How Much Does Peptide Manufacturing Cost with a US CDMO? Read More »
Introduction Evaluating a contract development and manufacturing organization (CDMO) for peptide active pharmaceutical ingredients (APIs) involves more than assessing conventional
Top Things to Look for in a GMP Peptide CDMO Partner Read More »
Introduction CMC Due Diligence Support involves a comprehensive assessment of the technical, regulatory, and quality aspects of drug substance and
CMC Due Diligence Support for Pharma Licensing Deals and Investor Audits Read More »
Introduction Overcoming Polymorphic Instability During NDA CMC Review requires the implementation of orthogonal solid-state characterization protocols, validation of robust crystallization
Introduction A well-prepared Common Technical Document (CTD) Module 3 serves as a comprehensive, reviewer-ready Chemistry, Manufacturing, and Controls (CMC) quality
Regulatory CMC Writing Services: What a Well-Prepared CTD Module 3 Looks Like Read More »
Introduction Scale-Up and Tech Transfer in CMC represents a critical operational pathway through which bench-scale drug formulation and synthesis are
Introduction FDA expectations for Extractables and Leachables in CMC require pharmaceutical sponsors to demonstrate chemical compatibility through risk-based material characterization,
Introduction Contract development and manufacturing organizations (CDMOs) that initially specialized in synthetic peptides have expanded their capabilities into nucleic acid